Treatment of children and adolescents with metastatic medulloblastoma and prognostic relevance of clinical and biologic parameters

• Verfasst von: Bueren, André von [VerfasserIn]
• Verfasst von: Kool, Marcel [VerfasserIn]
• Verfasst von: Pfister, Stefan [VerfasserIn]
• Titel: Treatment of children and adolescents with metastatic medulloblastoma and prognostic relevance of clinical and biologic parameters
• Verf.angabe: André O. von Bueren, Rolf-Dieter Kortmann, Katja von Hoff, Carsten Friedrich, Martin Mynarek, Klaus Müller, Tobias Goschzik, Anja zur Mühlen, Nicolas Gerber, Monika Warmuth-Metz, Niels Soerensen, Frank Deinlein, Martin Benesch, Isabella Zwiener, Robert Kwiecien, Andreas Faldum, Udo Bode, Gudrun Fleischhack, Volker Hovestadt, Marcel Kool, David Jones, Paul Northcott, Joachim Kuehl, Stefan Pfister, Torsten Pietsch and Stefan Rutkowski
• E-Jahr: 2016
• Jahr: October 3, 2016
• Umfang: 10 S.
• Fussnoten: Gesehen am 10.10.2017
• Titel Quelle: Enthalten in: Journal of clinical oncology
• Ort Quelle: Alexandria, Va. : American Society of Clinical Oncology, 1983
• Jahr Quelle: 2016
• Band/Heft Quelle: 34(2016), 34, Seite 4151-4160
• ISSN Quelle: 1527-7755
• DOI: doi:10.1200/JCO.2016.67.2428
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1564256596

Abstract

PurposeTo assess an intensified treatment in the context of clinical and biologic risk factors in metastatic medulloblastoma.Patients and MethodsPatients (4 to 21 years old, diagnosed between 2001 and 2007) received induction chemotherapy, dose-escalated hyperfractionated craniospinal radiotherapy, and maintenance chemotherapy. Subgroup status and other biologic parameters were assessed.ResultsIn 123 eligible patients (median age, 8.2 years old; median follow-up, 5.38 years), 5-year event-free survival (EFS) and overall survival (OS) were 62% (95% CI, 52 to 72) and 74% (95% CI, 66 to 82), respectively. OS was superior compared with the precedent HIT ’91 trial. The 5-year EFS and OS were both 89% (95% CI, 67 to 100) for desmoplastic/nodular (n = 11), 61% (95% CI, 51 to 71) and 75% (95% CI, 65 to 85) for classic (n = 107), and 20% (95% CI, 0 to 55) and 40% (95% CI, 0 to 83) for large-cell/anaplastic (n = 5) medulloblastoma (P < .001 for EFS; P = .001 for OS). Histology (hazard ratio, 0.19 for desmoplastic/nodular and 45.97 for large-cell/anaplastic medulloblastoma) and nonresponse to the first chemotherapy cycle (hazard ratio, 1.97) were independent risk factors (EFS). Among 81 (66%) patients with tumor material, 5-year EFS and OS differed between low-risk (wingless [WNT], n = 4; both 100%), high-risk (MYCC/MYCN amplification; n = 5, both 20%), and intermediate-risk patients (neither; n = 72, 63% and 73%, respectively). Survival rates were different between molecular subgroups (WNT, n = 4; sonic hedgehog [SHH; n = 4]; group 4 [n = 41]; group 3 with [n = 3] or without [n = 17] MYCC/MYCN amplification; P < .001). All cases showed p53 immuno-negativity. There was no association between patients with nonresponding tumors to induction chemotherapy and WNT (P = .143) or MYCC/MYCN status (P = .075), histologic subtype (P = .814), or molecular subtype (P = .383), as assessed by Fisher’s exact test.ConclusionThis regimen was feasible and conferred overall favorable survival. Our data confirm the relevance of subgroup status and biologic parameters (WNT/MYCC/MYCN status) in a homogeneous prospective trial population, and show that metastatic group 3 patients do not uniformly have poor outcomes. Biologic subgroup, MYCC/MYCN status, response to induction chemotherapy, and histologic subtype may serve for improved treatment stratification.